GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

BACKGROUND: GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nauck, Michael A., Quast, Daniel R., Wefers, Jakob, Meier, Juris J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085572/
https://www.ncbi.nlm.nih.gov/pubmed/33068776
http://dx.doi.org/10.1016/j.molmet.2020.101102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085572/
https://www.ncbi.nlm.nih.gov/pubmed/33068776
http://dx.doi.org/10.1016/j.molmet.2020.101102

Ejemplares similares